Biochemical and Pharmacological Differentiation of Generic Low Molecular Weight Heparins
نویسندگان
چکیده
منابع مشابه
Differentiation of the low-molecular-weight heparins.
The three low-molecular-weight heparins (LMWHs) available in the United States have been extensively evaluated for a wide array of indications. Properties associated with one LMWH cannot be assumed to be the same as those associated with another LMWH, as they are different pharmacologic entities. Therefore, therapeutic interchange of these agents is inappropriate. The pharmacokinetic and pharma...
متن کاملGeneric Low Molecular Weight Heparins: Where Do We Stand?
Unfractionated heparin and different brands of commercially available low molecular weight heparins (LMWHs) have made a major impact on the management of thrombotic disorders in the past 50 years. While the generic versions of unfractionated heparins have been developed in accordance to the initial manufacturing guidelines and subsequent Food and Drug Administration (FDA) mandates, the differen...
متن کاملVariability of heparins and heterogeneity of low molecular weight heparins.
Chemical and physical characteristics, building blocks, constitutive disaccharides, sulfation degree, and biological activities of heparins (UFHs) and of low molecular weight heparins (LMWHs) obtained by different depolymerization processes are examined comparatively in terms of structure characteristics, content of 1,6-anhydro rings, and other fingerprints. The heterogeneity of different LMWHs...
متن کاملLow-molecular-weight heparins and heparinoids.
Several low molecular weight (LMW) heparin preparations, including dalteparin, enoxaparin and nadroparin, as well as the heparinoid danaparoid sodium, are approved for use in Australia. LMW heparins are replacing unfractionated heparin for the prevention and treatment of venous thromboembolism and the treatment of non-ST-segment-elevation acute coronary syndromes. The advantages of LMW heparins...
متن کاملLow-molecular-weight heparins and angiogenesis.
The involvement of the vascular system in malignancy encompasses not only angiogenesis, but also systemic hypercoagulability and a pro-thrombotic state, and there is increasing evidence that pathways of blood coagulation and angiogenesis are reciprocally linked. In fact, cancer atients often display hypercoagulability resulting in markedly increased thromboembolism, which requires anti-coagulan...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The FASEB Journal
سال: 2007
ISSN: 0892-6638,1530-6860
DOI: 10.1096/fasebj.21.6.a1167-c